BioSpace News Archive

Turn-key solution for the sustainable advancement and growth of clinical research sites

EBR Systems, Inc., developer of the world’s only wireless cardiac pacing system for heart failure, today announced it has closed $30M in new funding to complete enrollment of its pivotal SOLVE CRT clinical trial and to prepare for commercialization of the WiSE Cardiac Resynchronization Therapy (CRT) System.

Cyrus Biotechnology, Inc. announces the availability of CryoEM services to generate high precision models from CryoEM data.

Celsius Holdings, Inc. (Nasdaq: CELH), maker of the leading global fitness drink, CELSIUS®, today announced that the company is expanding its product portfolio to include an innovative branched-chain amino acids (BCAA) functional beverage that fuels muscle recovery

Harbour BioMed (HBM), a global clinical-stage biopharmaceutical company, and Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization (CRO), today announced a strategic collaboration to develop HBM’s innovative therapeutics in the fields of oncology and immunology.

Therapix Biosciences Ltd. (“Therapix” or the “Company”) (NASDAQ: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today that the Nasdaq Stock Market has granted the Company an extension until November 18, 2019, to regain compliance with Nasdaq Listing Rule 5550(b)(1), which will permit the continued listing of Therapix’s stock on the Nasdaq Stock Market.

MedPharm Research, the leader in cannabis research and formulation development, was notified by the Drug Enforcement Administration that it had been selected to move forward as one of the first applicants to be granted a license to grow federally legal cannabis under the terms of a new policy statement issued in the Federal Register.